MORGAN STANLEY PLC/CALL/GILEAD SCIENCES/75/0.1/21.06.24 | Market Closed - Börse Stuttgart 02:33:27 2024-05-31 pm EDT | ||
| 0.012 EUR | -.--% |
|
| 1 month | -36.84% | ||
| 3 months | -95.00% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GILEAD SCIENCES, INC.
Latest news about GILEAD SCIENCES, INC.
| Date | Price | Change |
|---|---|---|
| 24-05-31 | 0.012 | -.--% |
| 24-05-30 | 0.012 | -7.69% |
| 24-05-29 | 0.013 | +30.00% |
| 24-05-28 | 0.01 | -.--% |
Delayed Quote Börse Stuttgart
Last update May 31, 2024 at 02:33 pm EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | GILEAD SCIENCES, INC. |
| Issuer | Morgan Stanley |
| WKN | MD7C7N |
| ISIN | DE000MD7C7N2 |
| Date issued | 2022-08-24 |
| Strike | 75 $ |
| Maturity | 2024-06-21 (17 Days) |
| Parity | 10 : 1 |
| Emission price | 0.56 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 2.05 € |
|---|---|
| Lowest since issue | 0.008 € |
Company Profile
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
-
Consensus: Gilead Sciences, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
64.16
USD
Average target price
82.7
USD
Spread / Average Target
+28.89%
- Stock Market
- Warrants
- Warrant
